Interpace Diagnostics (IDXG) Reports Q3 Loss of $0.11, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
November 13, 2018 4:18 PM ESTConference Call Tuesday, November 13, 2018 at 4:30 pm ET
PARSIPPANY, NJ,, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced financial results and business progress for the quarter ended September 30, 2018, as well as recent accomplishments.
Topline highlights include:
Expanded Guidance of Revenues for the Year to a Range between $21 and $22 MillionRevenue Grew to $5.8 Million in the Third Quarter... More